Dr. Alex Matter CML Chronic Myeloid Leukemia
''Dr. Alex Matter is best known for his contribution to the development of
Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against
chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr. Matter led a
team of close to 200 scientists at Novartis to discover and optimize the lead
compound and brought it all the way through its first clinical trial in 1998. In
a short span of 3 years, Glivec/Gleevec was given a very rare, fast track FDA
approval in 2001.''
Extract of CV of Alex Matter
ARTICLES
2013 Prize: Alex Matter, M.D.
April 6, 2013, National Foundation for Cancer Research
Dr. Alex Matter has been awarded the 8th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
January 29, 2013, National Foundation for Cancer research
Executive Summary of a Book: Magic Cancer Bullet
May 23, 2009, Discovery Medecine
2013 Prize: Alex Matter, M.D.
April 6, 2013, National Foundation for Cancer Research
Dr. Alex Matter has been awarded the 8th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
January 29, 2013, National Foundation for Cancer research
Executive Summary of a Book: Magic Cancer Bullet
May 23, 2009, Discovery Medecine
